Argenx SE: Overweight Rating Spurs Long‑Term Value in Biotechnology
Argenx SE’s “Overweight” upgrade by Barclays highlights its 5,685% decade‑long growth, strong biotech pipeline, and resilience amid European market volatility.
3 minutes to read
Argenx SE
Argenx SE Surpasses Market Expectations with Strong Financial Results and Stock Surge
Argenx SE, a leading biotechnology company, has reported impressive half-year financial results, exceeding market expectations with a GAAP EPS of $6.32 and revenue of $1.74 billion.
2 minutes to read
Argenx SE Prepares to Unveil H1 2025 Financial Results Amid Biotech Innovations
Argenx SE is preparing to release its financial results, highlighting the company’s ongoing commitment to advancing healthcare through innovative antibody-based therapies in the biotechnology industry.
2 minutes to read
Argenx SE Advances in Biotech with Upcoming Trial for Rare Disease
Argenx SE, a biotechnology company, is making significant strides in treating severe autoimmune diseases and cancer with its innovative antibody-based therapies, including a promising candidate set to enter a registrational trial for Congenital Myas…
2 minutes to read
Argenx SE Secures EU Approval for VYVGART, Revolutionizing CIDP Treatment
Argenx SE has secured European Commission approval for its innovative VYVGART subcutaneous injection, marking a significant milestone in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
3 minutes to read
Argenx SE Achieves Major Milestone with CHMP’s Positive Opinion for CIDP Treatment VYVGART
Argenx SE’s treatment VYVGART has received a positive opinion from the European CHMP, paving the way for potential approval and marking a significant milestone in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
3 minutes to read